Inhibikase Therapeutics, Inc.
IKT
$1.89
$0.042.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 46.15% | 71.69% | |||
| Gross Profit | -46.15% | -71.69% | |||
| SG&A Expenses | -8.47% | 250.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.92% | 121.86% | |||
| Operating Income | -21.92% | -121.86% | |||
| Income Before Tax | -12.74% | -109.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.74% | -109.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.74% | -109.98% | |||
| EBIT | -21.92% | -121.86% | |||
| EBITDA | -21.89% | -121.99% | |||
| EPS Basic | 9.21% | 74.13% | |||
| Normalized Basic EPS | 1.52% | 74.13% | |||
| EPS Diluted | 9.21% | 74.13% | |||
| Normalized Diluted EPS | 1.52% | 74.13% | |||
| Average Basic Shares Outstanding | 24.23% | 711.39% | |||
| Average Diluted Shares Outstanding | 24.23% | 711.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||